CompletedPhase 3NCT06049940
Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population
Studying Tetanus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sinovac Life Sciences Co., Ltd.
- Principal Investigator
- Zhiqing XieHenan Provincial Center for Disease Prevention and Control
- Intervention
- Investigational tetanus vaccine, adsorbed(biological)
- Enrollment
- 1260 enrolled
- Eligibility
- 18-44 years · All sexes
- Timeline
- 2023 – 2024
Study locations (1)
- Liangyuan District Center for Disease Control and Prevention, Shangqiu, Henan, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06049940 on ClinicalTrials.govOther trials for Tetanus
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1NCT07149454Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody InjectionLanzhou Institute of Biological Products Co., Ltd
- RECRUITINGNCT07107932A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following InjuryZhuhai Trinomab Pharmaceutical Co., Ltd.
- RECRUITINGPHASE3NCT06635798A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 InjectionGenrix (Shanghai) Biopharmaceutical Co., Ltd.